Building a Healthy Future Together – Welcome to CPHI & PMEC China 2026|Our booth No: W9A25|CongenPharma
Publish Time:
2026-05-25
As the semaglutide patent expiry reshapes the global GLP-1 landscape, securing a stable and cost‑effective supply of critical intermediates is more important than ever.
CongenPharm will be exhibiting at CPHI China 2026 (Jun 16‑18, SNIEC, Shanghai) with our proven EMPHASES® peptide synthesis platform and a full suite of semaglutide & tirzepatide intermediates—including Fmoc‑AEEA‑OH, Fmoc‑AEEA‑AEEA‑OH, and the oral permeation enhancer SNAC.
✅ Milligrams to tons—SCALABLE supply from R&D to commercial
✅ EMPHASES® platform—green, efficient, scalable, cost‑effective
✅ SNAC—the proven enhancer enabling oral peptide bioavailability
Visit us at CPHI China 2026. Our booth No: W9A25 Let’s build a resilient GLP-1 supply chain together.W
Emai: Email:marketing@congenpharm.com for details.
Prev:
Relevant Information
undefined
